These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 25039279)

  • 1. Evidence that the pregnane X and retinoid receptors PXR, RAR and RXR may regulate transcription of the transporter hOCT1 in chronic myeloid leukaemia cells.
    Austin G; Holcroft A; Rinne N; Wang L; Clark RE
    Eur J Haematol; 2015 Jan; 94(1):74-8. PubMed ID: 25039279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells.
    Wang L; Giannoudis A; Austin G; Clark RE
    Exp Hematol; 2012 Oct; 40(10):811-9.e2. PubMed ID: 22677017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [H-oCT1 gene expression as a predictor of major and complete molecular response to imatinib of chronic myeloid leukemia. Single center experience].
    Sacha T; Czekalska S; Foryciarz K; Zawada M; Florek I; Cwynar D; Wator G; Balwierz W; Skotnicki AB
    Przegl Lek; 2011; 68(4):191-5. PubMed ID: 21853672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells.
    Wang J; Lu L; Kok CH; Saunders VA; Goyne JM; Dang P; Leclercq TM; Hughes TP; White DL
    Haematologica; 2017 May; 102(5):843-853. PubMed ID: 28154092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.
    Giannoudis A; Wang L; Jorgensen AL; Xinarianos G; Davies A; Pushpakom S; Liloglou T; Zhang JE; Austin G; Holyoake TL; Foroni L; Kottaridis PD; Müller MC; Pirmohamed M; Clark RE
    Blood; 2013 Jan; 121(4):628-37. PubMed ID: 23223357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
    Ben Hassine I; Gharbi H; Soltani I; Teber M; Farrah A; Ben Hadj Othman H; Amouri H; Bellaaj H; Lakhal RB; Romdhane NB; Abbes S; Menif S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):737-745. PubMed ID: 28286932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human organic cation transporter 1 protein levels of granulocytes can optimize imatinib therapy in patients with chronic myeloid leukemia.
    Cao C; Li X; Liu T; Zhang L; Shen K; Zhu H
    Acta Haematol; 2015; 133(2):199-204. PubMed ID: 25358338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influence of hOCT1 polymorphism on imatinib mesylate effectiveness in chronic myelogenous leukemia patients].
    Hu N; Zhu HL; Liu HW; Zeng CX; Meng WT; Liu T
    Zhonghua Xue Ye Xue Za Zhi; 2009 Sep; 30(9):596-600. PubMed ID: 19954617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia.
    Vaidya S; Ghosh K; Shanmukhaiah C; Vundinti BR
    Eur J Pharmacol; 2015 Oct; 765():124-30. PubMed ID: 26300393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.
    Koren-Michowitz M; Buzaglo Z; Ribakovsky E; Schwarz M; Pessach I; Shimoni A; Beider K; Amariglio N; le Coutre P; Nagler A
    Eur J Haematol; 2014 Apr; 92(4):283-8. PubMed ID: 24215657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variations in influx transporter gene
    Makhtar SM; Husin A; Baba AA; Ankathil R
    J Genet; 2018 Sep; 97(4):835-842. PubMed ID: 30262695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnane X Receptor Expression in Human Pancreatic Adenocarcinoma: Associations With Clinicopathologic Parameters, Tumor Proliferative Capacity, Patients' Survival, and Retinoid X Receptor Expression.
    Koutsounas I; Giaginis C; Alexandrou P; Zizi-Serbetzoglou A; Patsouris E; Kouraklis G; Theocharis S
    Pancreas; 2015 Oct; 44(7):1134-40. PubMed ID: 26355550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinoid X Receptor Selective Agonists and their Synthetic Methods.
    Wagner CE; Jurutka PW; Marshall PA; Heck MC
    Curr Top Med Chem; 2017; 17(6):742-767. PubMed ID: 27320333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia.
    Nardinelli L; Sanabani SS; Didone A; Ferreira Pde B; Serpa M; Novaes MM; Marchiani M; Ruiz AL; Lima IS; Chamone Dde A; Bendit I
    Acta Haematol; 2012; 127(4):228-34. PubMed ID: 22508387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of hOCT1 in patients with chronic myelogeneous leukemia treated by imatinib mesylate].
    Zheng CX; Zhu HL; Liu HW; Hu N; Meng WT
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 40(5):893-6. PubMed ID: 19950608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OCT1 and imatinib transport in CML: is it clinically relevant?
    Watkins DB; Hughes TP; White DL
    Leukemia; 2015 Oct; 29(10):1960-9. PubMed ID: 26122430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity.
    Engler JR; Frede A; Saunders VA; Zannettino AC; Hughes TP; White DL
    Leukemia; 2010 Apr; 24(4):765-70. PubMed ID: 20147974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia.
    Di Paolo A; Polillo M; Capecchi M; Cervetti G; Baratè C; Angelini S; Guerrini F; Fontanelli G; Arici R; Ciabatti E; Grassi S; Bocci G; Hrelia P; Danesi R; Petrini M; Galimberti S
    Pharmacogenomics J; 2014 Aug; 14(4):328-35. PubMed ID: 24589908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
    Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
    Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.
    Roy S; Jørgensen HG; Roy P; Abed El Baky M; Melo JV; Strathdee G; Holyoake TL; Bartholomew C
    Br J Haematol; 2012 May; 157(4):446-56. PubMed ID: 22372463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.